NCT03530228 - A Phase 1 Study of Tegoprazan on Healthy Male Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2018

Primary Completion Date

August 31, 2018

Study Completion Date

August 31, 2018

Conditions

PharmacodynamicsPharmacokineticsHealthy Male Volunteers

Interventions

DRUG

Tegoprazan (C1)

Tegoprazan QD, oral administration. Treatment A

DRUG

Tegoprazan (C1)

Tegoprazan QD, oral administration. Treatment B

DRUG

Treatment C: Tegoprazan (C1)

Tegoprazan BID, oral administration

DRUG

Tegoprazan (C2)

Tegoprazan QD, oral administration, for 7 days. Group 1

DRUG

Tegoprazan (C2)

Tegoprazan QD, oral administration, for 7 days. Group 2

DRUG

Esomeprazole (C2)

Esomeprazole QD, oral administration, for 7 days. Group 3

DRUG

Tegoprazan (C3)

Tegoprazan QD, oral administration

Trial Locations (1)

RECRUITING

Seoul National University Hospital, Seoul